Quarterly Drug Approvals: July 2025 - Prime Therapeutics
publications
Quarterly Drug Approvals: July 2025
This report provides an overview of new drugs and indications approved in 2025
August 1, 2025
Specialty drug approvals
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
clesrovimab-cfor | Enflonsia | Merck | RSV LRTD prevention (neonates and infants) | IM | June |
garadacimab-gxii | Andembry | CSL Behring | Hereditary angioedema prophylaxis (≥ 12 years of age) |
SC | June |
immune globulin infusion (human) 10% solution | Gammagard Liquid ERC | Takeda | Primary humoral immunodeficiency (≥ 2 years of age) |
IV, SC | June |
lenacapavir oral tablet and SC injection | Yeztugo | Gilead | HIV-1 PrEP (patients weighing ≥ 35 kg) | Oral, SC | June |
nitisinone oral tablet | Harliku | Cycle | Alkaptonuria | Oral | June |
hydrocortisone oral solution | Khindivi | Eton | Adrenocortical insufficiency (≥ 5 years of age) |
Oral | May |
treprostinil inhalation powder | Yutrepia | Liquidia | Improve exercise ability in patients with: (1) PAH; (2) Pulmonary hypertension associated with interstitial lung disease | Oral inhalation | May |
atrasentan | Vanrafia | Novartis | Primary IgA nephropathy | Oral | April |
nipocalimab-aahu | Imaavy | Janssen | Generalized myasthenia gravis in patients ≥ 12 years of age who are anti-AChR or anti-MuSK antibody positive | IV | April |
diazoxide choline | Vykat XR | Soleno | Hyperphagia in Prader-Willi syndrome (≥ 4 years of age) |
Oral | March |
fitusiran | Qfitlia | Sanofi | Bleed prophylaxis in hemophilia A or B with or without inhibitors (≥ 12 years of age) | SC | March |
tesamorelin F8 formulation | Egrifta WR | Theratechnologies | HIV lipodystrophy | SC | March |
apomorphine HCl | Onapgo | Supernus | Advanced Parkinson's disease | SC (continuous infusion) | February |
chenodiol | Ctexli | Mirum | Cerebrotendinous xanthomatosis | Oral | February |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
belimumab | Benlysta | GlaxoSmithKline | Autoinjector approved for pediatric patients ≥ 5 years of age with lupus nephritis | SC | June |
dupilumab | Dupixent | Regeneron | Bullous pemphigoid | SC | June |
emapalumab-lzsg | Gamifant | Novimmune | Expanded indication to include hemophagocytic lymphohistiocytosis/ macrophage activation syndrome in Still's disease (newborn and older) | IV | June |
glecaprevir and pibrentasvir | Mavyret | Abbvie | Acute HCV infection (≥ 3 years of age) | Oral | June |
antihemophilic factor (recombinant), PEGylated-aucl | Jivi | Bayer | Expanded indication (≥ 7 years of age) for hemophilia A | IV | May |
mepolizumab | Nucala | GlaxoSmithKline | COPD with an eosinophilic phenotype | SC | May |
ranibizumab | Susvimo | Genentech | Diabetic retinopathy | Intravitreal | May |
dupilumab | Dupixent | Regeneron | Chronic spontaneous urticaria (≥ 12 years of age) |
SC | April |
inebilizumab-cdon | Uplizna | Amgen | IgG4-related disease | IV | April |
osilodrostat | Isturisa | Recordati Rare Diseases | Expanded indication for endogenous hypercortisolemia in Cushing's syndrome | Oral | April |
upadacitinib | Rinvoq | Abbvie | Giant cell arteritis | Oral | April |
fluocinolone acetonide | Iluvien | Ani | Chronic non-infectious uveitis affecting the posterior segment of the eye | Intravitreal | March |
furosemide | Furoscix | scPharmaceuticals | Edema in patients with CKD | SC (continuous infusion) | March |
guselkumab | Tremfya | Janssen | Crohn's disease | IV, SC | March |
iptacopan | Fabhalta | Novartis | Complement 3 glomerulopathy | Oral | March |
nedosiran | Rivfloza | Novo Nordisk | Expanded indication (≥ 2 years of age) for primary hyperoxaluria type 1 | SC | March |
vutrisiran | Amvuttra | Alnylam | Transthyretin amyloid cardiomyopathy (ATTR-CM) | SC | March |
eculizumab | Soliris | Alexion | Expanded indication (≥ 6 years of age) for generalized myasthenia gravis | IV | February |
ranibizumab | Susvimo | Genentech | Diabetic macular edema | Intravitreal | February |
esketamine | Spravato | Janssen | Monotherapy for treatment-resistant depression | Intranasal | January |
mirikizumab-mrkz | Omvoh | Eli Lilly | Crohn's disease | IV, SC | January |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
mitomycin intravesical solution | Zusduri | Urogen | Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | Intravesical | June |
taletrectinib | Ibtrozi | Nuvation Bio | Locally advanced or metastatic ROS1+ NSCLC | Oral | June |
avutometinib; defactinib | Avmapki Fakzynja Co-Pack | Verastem | KRAS-mutated recurrent low-grade serous ovarian cancer | Oral | May |
telisotuzumab vedotin-tllv | Emrelis | Abbvie | Locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | IV | May |
penpulimab-kcqx | no trade name | Akeso | (1) Recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in combination with cisplatin or carboplatin and gemcitabine; (2) Metastatic non-keratinizing NPC with progression after prior therapy | IV | April |
mirdametinib | Gomekli | SpringWorks | Neurofibromatosis type 1-associated plexiform neurofibromas (≥ 2 years of age) | Oral | February |
vimseltinib | Romvimza | Deciphera | Symptomatic tenosynovial giant cell tumor | Oral | February |
datopotamab deruxtecan-dlnk | Datroway | Daiichi Sankyo | Unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer | IV | January |
treosulfan | Grafapex | Medexus | Preparative regimen for allogeneic HSCT in combination with fludarabine for patients with AML or MDS (≥ 1 year of age ) | IV | January |
nilotinib d-tartrate | no trade name | Cipla | Newly diagnosed Ph+ CML in chronic phase (CP); (2) CP and accelerated phase Ph+ CML resistant to imatinib | Oral | February |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
darolutamide | Nubeqa | Bayer | Metastatic castration-sensitive prostate cancer as a single agent | Oral | June |
datopotamab deruxtecan-dlnk | Datroway | Daiichi Sankyo | Locally advanced or metastatic EGFR-mutated NSCLC | IV | June |
pembrolizumab | Keytruda | Merck Sharp and Dohme | Resectable locally advanced head and neck squamous cell carcinoma with tumors expressing PD-L1 | IV | June |
tafasitamab-cxix | Monjuvi | Incyte | R/R follicular lymphoma in combination with lenalidomide and rituximab | IV | June |
belzutifan | Welireg | Merck Sharp and Dohme | Locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma (≥ 12 years of age) | Oral | May |
retifanlimab-dlwr | Zynyz | Incyte | (1) Locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) in combination with carboplatin and paclitaxel; (2) Locally recurrent or metastatic SCAC with disease progression as a single agent | IV | May |
ipilimumab | Yervoy | Bristol-Myers Squibb | Indication for MSI-H or dMMR CRC in combination with Opdivo expanded to include treatment-naïve patients (≥ 12 years of age) | IV | April |
ipilimumab | Yervoy | Bristol-Myers Squibb | Indication for unresectable or metastatic HCC in combination with Opdivo expanded to include treatment-naïve patients | IV | April |
nivolumab | Opdivo | Bristol-Myers Squibb | Indication for MSI-H or dMMR CRC in combination with Yervoy expanded to include treatment-naïve patients (≥ 12 years of age) | IV | April |
nivolumab | Opdivo | Bristol-Myers Squibb | Indication for unresectable or metastatic HCC in combination with Yervoy expanded to include treatment-naïve patients | IV | April |
palbociclib | Ibrance | Pfizer | PIK3CA-mutated, HR+, HER2- locally advanced or metastatic breast cancer in combination with Itovebi and Faslodex | Oral | April |
cabozantinib | Cabometyx | Exelixis | Pancreatic and extra-pancreatic neuroendocrine tumors (≥ 12 years of age) | Oral | March |
durvalumab | Imfinzi | AstraZeneca | Neoadjuvant and adjuvant treatment for muscle invasive bladder cancer | IV | March |
tislelizumab-jsgr | Tevimbra | BeiGene | First line for advanced esophageal squamous cell carcinoma in combination with platinum-containing chemotherapy | IV | March |
brentuximab vedotin | Adcetris | Seagen | R/R large B-cell lymphoma in combination with lenalidomide and rituximab | IV | February |
acalabrutinib | Calquence | AstraZeneca | Untreated mantle cell lymphoma in combination with bendamustine and rituximab | Oral | January |
fam-trastuzumab deruxtecan-nxki | Enhertu | Daiichi Sankyo | Unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer | IV | January |
panitumumab | Vectibix | Amgen | KRAS G12C-mutated metastatic colorectal cancer in combination with sotorasib | IV | January |
sotorasib | Lumakras | Amgen | KRAS G12C-mutated metastatic colorectal cancer in combination with panitumumab | Oral | January |
Traditional drug approvals
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
lisdexamfetamine dimesylate oral solution | Arynta | Azurity | (1) ADHD (≥ 6 years of age); (2) Binge eating disorder | Oral | June |
telmisartan/ amlodipine/ indapamide | Widaplik | George Medicines | HTN | Oral | June |
acoltremon | Tryptyr | Alcon | Dry eye disease | Ophthalmic | May |
dihydroergotamine injection | Brekiya | Amneal | Acute treatment of migraine and cluster headaches | SC | May |
aripiprazole oral film | Mezofy | CMG | Schizophrenia (≥ 13 years of age) | Oral | April |
dihydroergotamine nasal powder | Atzumi | Satsuma | Acute treatment of migraine | Intranasal | April |
metoprolol tartrate oral solution | Lopressor | Validus | (1) HTN; (2) Long-term treatment of angina pectoris; (3) Hemodynamically stable patients with MI in conjunction with IV metoprolol | Oral | April |
chlorthalidone | Hemiclor | PRM | HTN | Oral | March |
gepotidacin | Blujepa | GSK | Uncomplicated UTI (females ≥ 12 years of age) | Oral | March |
losartan oral suspension | Arbli | Scienture | (1) HTN (> 6 years of age); (2) Risk reduction in patients with HTN and LVH; (3) Diabetic nephropathy | Oral | March |
aztreonam / avibactam | Emblaveo | Abbvie | Complicated intra-abdominal infections in combination with metronidazole | IV | February |
copper intrauterine system | Miudella | Sebela Women's Health | Pregnancy prevention for up to 3 years | Intrauterine | February |
hydrochlorothiazide oral suspension | Inzirqo | Ani | Adults and pediatric patients with (1) HTN; (2) edema associated with CHF, hepatic cirrhosis and renal disease | Oral | January |
meloxicam / rizatriptan | Symbravo | Axsome | Acute treatment of migraine | Oral | January |
sitagliptin oral solution | Brynovin | Azurity | T2DM | Oral | January |
suzetrigine | Journavx | Vertex | Moderate to severe acute pain | Oral | January |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
cobicistat | Tybost | Gilead | Indication for HIV-1 expanded to include: (1) pediatric patients weighing ≥ 14 kg to < 35 kg in combination with atazanavir and other ARVs except for tenofovir alafenamide; (2) pediatric patients weighing ≥ 15 kg to < 40 kg in combination with darunavir and other ARVs | Oral | June |
emtricitabine/ tenofovir alafenamide fumarate | Descovy | Gilead | Indication for HIV-1 expanded to include pediatric patients weighing ≥ 14 kg to < 35 kg in combination with other ARVs, including darunavir and cobicistat, but not other protease inhibitors that require a CYP3A inhibitor |
Oral | June |
roflumilast 0.3% foam | Zoryve | Arcutis | Plaque psoriasis of the scalp and body (≥ 12 years of age) | Topical | May |
apixaban | Eliquis | Bristol-Myers Squibb | Expanded indication (pediatric patients from birth) for treatment of VTE and risk reduction for recurrent VTE | Oral | April |
dexamethasone ophthalmic insert | Dextenza | Ocular Therapeutix | Indications expanded to include pediatric patients: (1) ocular inflammation and pain following ophthalmic surgery; (2) allergic conjunctivitis (≥ 2 years of age) | Ophthalmic insert | April |
diazepam nasal spray | Valtoco | Neurelis | Expanded indication (≥ 2 years of age) for epilepsy | Intranasal | April |
palonosetron | Posfrea | Avyxa | Expanded indication (1 month to < 17 years of age) for chemotherapy-induced nausea and vomiting | IV | April |
tedizolid | Sivextro | Cubist | Indication for ABSSSI expanded to include (1) patients < 12 years of age weighing ≥ 35 kg (oral); (2) patients ≥ 26 weeks gestational age and weighing ≥ 1 kg (IV) |
IV, Oral | April |
darunavir / cobicistat | Prezcobix | Janssen | Expanded indication (≥ 25 kg to < 40 kg) for HIV-1 infection | Oral | March |
epinephrine nasal spray | Neffy | ARS | Expanded indication (≥ 4 years of age weighing ≥ 15 kg) for type I allergic reactions | Intranasal | March |
glucagon nasal powder | Baqsimi | Amphastar | Expanded indication (1 to 3 years of age) for severe hypoglycemia | Intranasal | March |
emtricitabine / rilpivirine / tenofovir alafenamide | Odefsey | Gilead | Expanded indication (≥ 25 kg to < 35 kg) for HIV-1 infection | Oral | February |
house dust mite (Dermatophagoides farinae & Dermatophagoides pteronyssinus) allergen extract | Odactra | ALK-Abello | Expanded indication (5 to 11 years of age) for house dust mite-induced allergic rhinitis | Oral | February |
moxidectin | no trade name | Medicines Development for Global Health | Expanded indication (4 to < 12 years of age) for onchocerciasis | Oral | February |
semaglutide | Ozempic | Novo Nordisk | Reduce risk of worsening kidney disease and CV death in patients with T2DM and CKD | SC | January |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
COVID-19 vaccine, adjuvanted | Nuvaxovid | Novavax | Active immunization to prevent COVID-19 in: (1) adults ≥ 65 years of age; (2) high-risk patients 12 to 64 years of age | IM | May |
COVID-19 vaccine, mRNA | mNexspike | Moderna | Active immunization to prevent COVID-19 in: (1) adults ≥ 65 years of age; (2) high-risk patients 12 to 64 years of age | IM | May |
smallpox and mpox vaccine, live, non-replicating, freeze-dried formulation | Jynneos | Bavarian Nordic | Prevention of smallpox and mpox disease | IM | March |
chikungunya vaccine, recombinant | Vimkunya | Bavarian Nordic | Prevention of chikungunya virus disease (≥ 12 years of age) | IM | February |
meningococcal groups A, B, C, W and Y vaccine | Penmenvy | GSK | Prevention of disease caused by Neisseria meningitidis serogroups A, B, C, W and Y (10 through 25 years of age) | IM | February |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
RSV vaccine | mResvia | Moderna | Indication for prevention of LRTD caused by RSV expanded to include patients 18 through 59 years of age who are at increased risk | IM | June |
meningococcal (groups A, C, Y, W) conjugate vaccine | MenQuadfi | Sanofi Pasteur | Indication for prevention of invasive meningococcal disease expanded to include patients 6 weeks to 23 months of age | IM | May |
Gene and cellular therapy and biosimilar approvals
Generic name | Brand name | Reference product | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|---|
ustekinumab-hmny | Starjemza (interchangeable) | Stelara | Bio-Thera / Hikma | Autoimmune disorders | IV, SC | May |
bevacizumab-nwgd | Jobevne | Avastin | Biocon | Select patients with CRC, NSCLC, glioblastoma, RCC, cervical cancer and epithelial ovarian, fallopian tube or primary peritoneal cancer | IV | April |
denosumab-bnht | Bomyntra | Xgeva | Fresenius Kabi | Bone health | SC | March |
denosumab-bnht | Conexxence | Prolia | Fresenius Kabi | Bone health | SC | March |
omalizumab-igec | Omlyclo (interchangeable) | Xolair | Celltrion | (1) Asthma; (2) Chronic rhinosinusitis with nasal polyps; (3) IgE-mediated food allergies; (4) Chronic spontaneous urticaria | SC | March |
denosumab-bmwo | Osenvelt | Xgeva | Celltrion | Bone health | SC | February |
denosumab-bmwo | Stoboclo | Prolia | Celltrion | Bone health | SC | February |
denosumab-dssb | Ospomyv | Prolia | Samsung Bioepis | Bone health | SC | February |
denosumab-dssb | Xbryk | Xgeva | Samsung Bioepis | Bone health | SC | February |
insulin aspart-szjj | Merilog, Merilog SoloStar | Novolog | Sanofi-Aventis | Diabetes mellitus | SC | February |
tocilizumab-anoh | Avtozma | Actemra | Celltrion | Autoimmune disorders and COVID-19 | IV, SC | January |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
rituximab-abbs | Truxima | Teva | Pemphigus vulgaris | IV | June |
rituximab-arrx | Riabni | Amgen | Pemphigus vulgaris | IV | June |
rituximab-pvvr | Ruxience | Pfizer | Pemphigus vulgaris | IV | June |
filgrastim-ayow | Releuko | Kashiv Biosciences | (1) Autologous hematopoietic progenitor cell mobilization for leukapheresis collection; (2) Hematopoietic syndrome of acute radiation syndrome | SC | April |
pegfilgrastim-pbbk | Fylnetra | Kashiv Biosciences | Hematopoietic subsyndrome of acute radiation syndrome | SC | April |
tocilizumab-aazg | Tyenne | Fresenius Kabi | (1) Hospitalized adults with COVID-19; (2) CAR T cell-induced CRS (≥ 2 years of age) | IV | February |
Generic name | Brand name | Manufacturer | Indication(s) | Route of administration | Month approved* |
---|---|---|---|---|---|
prademagene zamikeracel | Zevaskyn | Abeona | Recessive dystrophic epidermolysis bullosa | Surgical - Topical | April |
revakinagene taroretcel-lwey | Encelto | Neurotech | Macular telangiectasia type 2 | Intravitreal | March |
None
AAVRh74var adeno-associated virus serotype Rh74var
ABSSSI acute bacterial skin and skin structure infections
AchR acetylcholine receptor
ADHD attention deficit hyperactivity disorder
ALK anaplastic lymphoma kinase
ALK+ anaplastic lymphoma kinase-positive
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AQP4 anti-aquaporin-4
ARV antiretroviral
BPH benign prostatic hyperplasia
BRAF v-raf murine sarcoma viral oncogene homolog B1
CAR chimeric antigen receptor
CD19+ cluster of differentiate 19-positive
CD22+ cluster of differentiate 22-positive
CFTR cystic fibrosis transmembrane conductance regulator
CHF congestive heart failure
CIDP chronic inflammatory demyelinating polyneuropathy
CKD chronic kidney disease
CML chronic myeloid leukemia
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 2019
CRC colorectal cancer
CRS cytokine release syndrome
CV cardiovascular
CVD cardiovascular disease
CYP cytochrome P450
DMD Duchenne muscular dystrophy
dMMR deficient mismatch repair
EGFR epidermal growth factor receptor
ER extended release
ERC enhanced removal capability
FGFR3 fibroblast growth factor receptor 3
GERD gastroesophageal reflux disease
GVHD graft versus host disease
HCC hepatocellular carcinoma
HCI hydrochloride
HER2 human epidermal growth factor receptor 2
HER2+ human epidermal growth factor receptor 2-positive
HER2- human epidermal growth factor receptor 2-negative
HF heart failure
HIV-1 human immunodeficiency virus type-1
HR hormone receptor
HR+ hormone receptor-positive
HSCT hematopoietic stem cell transplant
HTN hypertension
Ig immunoglobulin
IDH isocitrate dehydrogenase
IHC immunohistochemistry
IM intramuscular
ISH in situ hybridization
IV intravenous
KMT2A lysine methyltransferase 2A gene
KRAS Kirsten rat sarcoma virus
LEPR leptin receptor
LRTD lower respiratory tract disease
LVH left ventricular hypertrophy
MDS myelodysplastic syndrome
mFOLFOX6 fluorouracil, leucovorin, oxaliplatin
MI myocardial infarction
MSI-H microsatellite instability-high
MuSK muscle-specific tyrosine kinase
NRG1+ neuregulin 1-positive
NSCLC non-small cell lung cancer
NTRK neurotrophic tyrosine receptor kinase
ODT orally disintegrating tablet
PAH pulmonary arterial hypertension
PCSK1 proprotein convertase subtilisin/kexin type 1
PD-L1+ programmed death-ligand 1-positive
Ph+ Philadelphia chromosome-positive
Ph- Philadelphia chromosome-negative
PIK3CA phosphatidylinositol-3-kinase catalytic subunit alpha
POMC pro-opiomelanocortin
PrEP pre-exposure prophylaxis
R/R relapsed or refractory
RET rearranged during transfection
RNA ribonucleic acid
RSV respiratory syncytial virus
SC subcutaneous
SCLC small cell lung cancer
sJIA systemic juvenile idiopathic arthritis
T2DM type 2 diabetes mellitus
UTI urinary tract infection
VEGF vascular endothelial growth factor
VTE venous thromboembolism
XR extended release
ABSSSI acute bacterial skin and skin structure infections
AchR acetylcholine receptor
ADHD attention deficit hyperactivity disorder
ALK anaplastic lymphoma kinase
ALK+ anaplastic lymphoma kinase-positive
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AQP4 anti-aquaporin-4
ARV antiretroviral
BPH benign prostatic hyperplasia
BRAF v-raf murine sarcoma viral oncogene homolog B1
CAR chimeric antigen receptor
CD19+ cluster of differentiate 19-positive
CD22+ cluster of differentiate 22-positive
CFTR cystic fibrosis transmembrane conductance regulator
CHF congestive heart failure
CIDP chronic inflammatory demyelinating polyneuropathy
CKD chronic kidney disease
CML chronic myeloid leukemia
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 2019
CRC colorectal cancer
CRS cytokine release syndrome
CV cardiovascular
CVD cardiovascular disease
CYP cytochrome P450
DMD Duchenne muscular dystrophy
dMMR deficient mismatch repair
EGFR epidermal growth factor receptor
ER extended release
ERC enhanced removal capability
FGFR3 fibroblast growth factor receptor 3
GERD gastroesophageal reflux disease
GVHD graft versus host disease
HCC hepatocellular carcinoma
HCI hydrochloride
HER2 human epidermal growth factor receptor 2
HER2+ human epidermal growth factor receptor 2-positive
HER2- human epidermal growth factor receptor 2-negative
HF heart failure
HIV-1 human immunodeficiency virus type-1
HR hormone receptor
HR+ hormone receptor-positive
HSCT hematopoietic stem cell transplant
HTN hypertension
Ig immunoglobulin
IDH isocitrate dehydrogenase
IHC immunohistochemistry
IM intramuscular
ISH in situ hybridization
IV intravenous
KMT2A lysine methyltransferase 2A gene
KRAS Kirsten rat sarcoma virus
LEPR leptin receptor
LRTD lower respiratory tract disease
LVH left ventricular hypertrophy
MDS myelodysplastic syndrome
mFOLFOX6 fluorouracil, leucovorin, oxaliplatin
MI myocardial infarction
MSI-H microsatellite instability-high
MuSK muscle-specific tyrosine kinase
NRG1+ neuregulin 1-positive
NSCLC non-small cell lung cancer
NTRK neurotrophic tyrosine receptor kinase
ODT orally disintegrating tablet
PAH pulmonary arterial hypertension
PCSK1 proprotein convertase subtilisin/kexin type 1
PD-L1+ programmed death-ligand 1-positive
Ph+ Philadelphia chromosome-positive
Ph- Philadelphia chromosome-negative
PIK3CA phosphatidylinositol-3-kinase catalytic subunit alpha
POMC pro-opiomelanocortin
PrEP pre-exposure prophylaxis
R/R relapsed or refractory
RET rearranged during transfection
RNA ribonucleic acid
RSV respiratory syncytial virus
SC subcutaneous
SCLC small cell lung cancer
sJIA systemic juvenile idiopathic arthritis
T2DM type 2 diabetes mellitus
UTI urinary tract infection
VEGF vascular endothelial growth factor
VTE venous thromboembolism
XR extended release
*Disclaimer: Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product’s manufacturer.
All brand names are property of their respective owners.